[QTc prolongation during treatment with agomelatine].

Psychiatr Prax

Asklepiosklinik Stadtroda, Stadtroda.

Published: November 2010

A 58 years old woman with a depression showed a QTc prolongation during treatment with agomelatine which was fully reversible after stopping administration. QTc prolongation during antidepressant treatment is not unknown especially when tricyclic antidepressants are administered. This case is the first occurrence of a QTc prolongation during treatment with agomelatine.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0030-1248578DOI Listing

Publication Analysis

Top Keywords

prolongation treatment
12
qtc prolongation
12
treatment agomelatine
8
[qtc prolongation
4
treatment
4
treatment agomelatine]
4
agomelatine] years
4
years woman
4
woman depression
4
depression qtc
4

Similar Publications

Background: Early mobilization of critical ill patients in the intensive care unit (ICU) has a positive effect on outcome. Currently, due to concerns of cerebral vasospasm and rebleeding patients with subarachnoid hemorrhage (SAH) have a prolong bedrest for 12-14 days.

Objective: What effect does early mobilization have on vasospasm, clinical outcome, length of stay and ICU complication rate in patients with SAH compared to standard treatment?

Methods: A systematic literature search was conducted in MEDLINE via the PubMed® (U.

View Article and Find Full Text PDF

This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals in China. Adults who were histologically diagnosed and never treated for extensive-stage small cell lung cancer (ES-SCLC) were enrolled.

View Article and Find Full Text PDF

Background: One of the common complications in spinal surgery patients is deep surgical site infections (SSIs). Deep SSIs refer to infections that involve the deeper soft tissues of the incision, such as the fascia and muscle layers. This complication can lead to prolonged hospitalization, repeated surgeries, and even life-threatening conditions.

View Article and Find Full Text PDF

Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies have triggered the exploration of non-invasive alternatives, such as radiomics, to comprehensively evaluate TIME across diverse cancers. To address these challenges, we develop an ICI response signature by integrating radiomics with T cell-inflamed gene-expression profiles.

View Article and Find Full Text PDF

FAP-targeted radioligand therapy with Ga/Lu-DOTA-2P(FAPI) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy.

J Immunother Cancer

January 2025

Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China

Background: Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, Ga/Lu-DOTA-2P(FAPI), which demonstrated increased tumor uptake and prolonged retention in various cancers. However, further exploration is required to understand the therapeutic efficacy and underlying mechanisms of combining Ga/Lu-DOTA-2P(FAPI) radioligand therapy with PD-1/PD-L1 immunotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!